Discover NOVA's MiDD approach
NOVA’s modeling and simulation approach combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform called Jinkō®. NOVA builds disease and treatment computational models based on knowledge extracted from literature and data. To simulate a trial, we run those models on virtual patients with appropriate simulated scenarios (in silico experimental protocols) to predict the clinical efficacy of new drugs at the population level before in-human trials take place
Are you planning for your upcoming MiDD (Model-informed Drug Development) programs? Do you want to learn more about the methodology behind in silico clinical trials? Download our white paper.Download our White Paper
Content of the case study
How do in silico clinical trials work?
NOVA builds disease and treatment computational models based on knowledge extracted from literature and data. To simulate a trial, we run those models on virtual patients with appropriate simulated scenarios (in silico experimental protocols) to predict the clinical efficacy of new drugs at the population level before in-human trials take place.
How do we build models?
NOVA's approach combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform Jinkō®, in 6 stages: the problem formulation, the systemic knowledge review, the computational models, the calibration, the model validation and the simulation.
What are the applications?
NOVA’s Model-informed Drug Development (MiDD) approach yields applications spanning the entire R&D spectrum, from systematic target combination exploration to value demonstration to payers: from the discovery stage to pricing and market access.